A Potential Dubin-Johnson Syndrome Imaging Agent: Synthesis, Biodistribution, and MicroPET Imaging

Yoo, Jeongsoo; Reichert, David E.; Kim, Joon‐Young; Anderson, Carolyn J.; Welch, Michael J.

doi:10.1162/15353500200504160

Cited by 7 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the ATSM analog has been used as a bifunctional chelator to attach Cu radionuclides to peptides. Several other small molecules have been labeled with 64 Cu (Figure ), for instance, a series of tetraaza macrocyclic ligands with methanephosphonate pendant arms showing a therapeutic effect on bone tumors or 1,4,7-tris(carboxymethyl)-10-(tetradecyl)-1,4,7,10-tetraazadodecane, which was shown to be an agent to diagnose Dubin–Johnson Syndrome (DJS).…”

Section: Radionuclides For Imaging and Therapymentioning

confidence: 99%

Radiometals for Combined Imaging and Therapy

et al. 2012

View full text Add to dashboard Cite

Section: Radionuclides For Imaging and Therapymentioning

confidence: 99%

Radiometals for Combined Imaging and Therapy

et al. 2012

View full text Add to dashboard Cite

“…Copper-64 macrocycles have been evaluated as substrates for the organic anion transporter for potential use as a diagnostic tool for Dubin-Johnson's syndrome. Small animal studies indicated that the cMOAT was involved in the excretion of the Cu-64 complex of compound 5 (47). A gene mutation of this organic anion transporter appears to cause Dubin-Johnson syndrome in humans (48).…”

Section: Membrane Transportmentioning

confidence: 99%

Future Direction of Renal Positron Emission Tomography

Szabó

Xia

Mathews

et al. 2006

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

Positron emission tomography (PET) is perfectly suited for quantitative imaging of the kidneys, and the recent improvements in detector technology, computer hardware, and image processing software add to its appeal. Multiple positron emitting radioisotopes can be used for renal imaging. Some, including carbon-11, nitrogen-13, and oxygen-15, can be used at institutions with an on-site cyclotron. Other radioisotopes that may be even more useful in a clinical setting are those that either can be obtained from radionuclide generators (rubidium-82, copper-62) or have a sufficiently long half-life for transportation (fluorine-18). The clinical use of functional renal PET studies (blood flow, glomerular filtration rate) has been slow, in part because of the success of concurrent technologies, including single-photon emission computed tomography (SPECT) and planar gamma camera imaging. Renal blood flow studies can be performed with O-15-labeled water, N-13-labeled ammonia, rubidium-82, and copper-labeled PTSM. With these tracers, renal blood flow can be quantified using a modified microsphere kinetic model. Glomerular filtration can be imaged and quantified with gallium-68 EDTA or cobalt-55 EDTA. Measurements of renal blood flow with PET have potential applications in renovascular disease, in transplant rejection or acute tubular necrosis, in drug-induced nephropathies, ureteral obstruction, before and after revascularization, and before and after the placement of ureteral stents. The most important clinical application for imaging glomerular function with PET would be renovascular hypertension. Molecular imaging of the kidneys with PET is rather limited. At present, research is focused on the investigation of metabolism (acetate), membrane transporters (organic cation and anion transporters, pepT1 and pepT2, GLUT, SGLT), enzymes (ACE), and receptors (AT1R). Because many nephrological and urological disorders are initiated at the molecular and organelle levels and may remain localized at their origin for an extended period of time, new disease-specific molecular probes for PET studies of the kidneys need to be developed. Future applications of molecular renal imaging are likely to involve studies of tissue hypoxia and apoptosis in renovascular renal disease, renal cancer, and obstructive nephropathy, monitoring the molecular signatures of atherosclerotic plaques, measuring endothelial dysfunction and response to balloon revascularization and restenosis, molecular assessment of the nephrotoxic effects of cyclosporine, anticancer drugs, and radiation therapy. New radioligands will enhance the staging and follow-up of renal and prostate cancer. Methods will be developed for investigation of the kinetics of drug-delivery systems and delivery and deposition of prodrugs, reporter gene technology, delivery of gene therapy (nuclear and mitochondrial), assessment of the delivery of cellular, viral, and nonviral vectors (liposomes, polycations, fusion proteins, electroporation, hematopoietic stems cells). Of particular importance ...

show abstract

“…Biliary scintigraphy with agents such as 99m Tc-lidofenin or 99m TC-disofenin may be helpful in the evaluation of patients with Dubin-Johnson and Rotor syndromes [204][205][206]. In six patients with Dubin-Johnson syndrome, administration of 99m Tc-lidofenin was followed by rapid, intense, homogeneous accumulation of isotope within the liver without visualization of the intrahepatic biliary tree [204].…”

Section: Imaging Studiesmentioning

confidence: 99%